AADI vs. CYBN, MCRB, NKTX, KYTX, BDTX, GLSI, BIOA, LFVN, HURA, and CLYM
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Cybin (CYBN), Seres Therapeutics (MCRB), Nkarta (NKTX), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Greenwich LifeSciences (GLSI), BioAge Labs (BIOA), Lifevantage (LFVN), TuHURA Biosciences (HURA), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry.
Aadi Bioscience vs. Its Competitors
Aadi Bioscience (NASDAQ:AADI) and Cybin (NYSE:CYBN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.
Cybin has a consensus price target of $85.00, indicating a potential upside of 1,012.57%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Aadi Bioscience.
Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Cybin has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
Cybin has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Cybin's return on equity of -37.58% beat Aadi Bioscience's return on equity.
Cybin has lower revenue, but higher earnings than Aadi Bioscience. Cybin is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Cybin had 6 more articles in the media than Aadi Bioscience. MarketBeat recorded 6 mentions for Cybin and 0 mentions for Aadi Bioscience. Cybin's average media sentiment score of 0.24 beat Aadi Bioscience's score of 0.00 indicating that Cybin is being referred to more favorably in the news media.
Summary
Cybin beats Aadi Bioscience on 10 of the 15 factors compared between the two stocks.
Get Aadi Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aadi Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:AADI) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access